. 2013 Aug 2;3(8):e129. doi: 10.1038/bcj.2013.27

Table 3. Summary of consensus LAPs.

Aberrant immunophenotypes	Number of cases	% of total number of LAPs	Used as best consensus LAPs (% of patients)a
LAPs with immature markers (n=125)b
Cross-lineage antigen expression (n=42)	n=42	29.4
CD7	26	18.2	36
CD34⁺ MM⁺ CD7⁺	11
CD117⁺MM⁺CD7⁺	8
CD34⁺CD117⁺CD7⁺	3
CD117⁺CD133⁺CD7⁺	3
CD34⁺CD133⁺CD7⁺	1
CD22	6	4.2	<10
CD34⁺ MM⁺ CD22⁺	4
CD117⁺ MM⁺ CD22⁺	1
CD34⁺ CD133⁺ CD22⁺	1
CD56	5	3.5	<10
CD34⁺ MM⁺ CD56⁺	4
CD133⁺ MM⁺ CD56⁺	1
CD19	3	2.1	<10
CD117⁺ MM⁺ CD19⁺	2
CD34⁺ MM⁺ CD19⁺	1
CD2	2	1.4	<10
CD34⁺ MM⁺ CD2⁺	1
CD34⁺ CD117⁺ CD2⁺	1
Asynchronous antigen expression (n=73)c	n=73	51,0
CD34^neg CD133⁺	14	9.8	20
CD34^neg CD133⁺ CD117⁺	13
CD34^neg CD133⁺⁺ CD33⁺	1
CD15	19	13.2	28
CD34⁺ MM⁺ CD15⁺	7
CD133⁺ MM⁺ CD15⁺	4
CD117⁺ MM⁺ CD15⁺	3
CD34⁺ CD133⁺ CD15⁺	3
CD133⁺ MM⁺ CD15⁺	1
CD117⁺ MM⁺ CD15⁺	1
CD13^neg	9	6.3	<10
CD34⁺ CD117⁺ CD13^neg	4
CD133⁺ MM⁺ CD13^neg	2
CD34⁺ CD133⁺ CD13^neg	1
CD34⁺ MM⁺ CD13^neg	1
CD117⁺ MM⁺ CD13^neg	1
HLA-DR^neg	8	5.6	20
CD34⁺ CD117⁺ HLA-DR^neg	4
CD34⁺ MM⁺ HLA-DR^neg	2
CD133⁺ CD117⁺ HLA-DR^neg	1
CD117⁺ MM^dim HLA-DR^neg	1
CD33^neg	7	4.9	11
CD34⁺ MM⁺ CD33^neg	7
CD36⁺ (see legend)	6	4.2	See legends
CD34⁺ CD117⁺ CD36⁺	3
CD34⁺ CD133⁺ CD36⁺	1
CD133⁺ MM⁺ CD36⁺	1
CD117⁺ CD34^neg CD36⁺	1
CD11b⁺	5	3.5	<10
CD117⁺ MM⁺ CD11b⁺	4
CD34⁺ MM⁺ CD11b⁺	1
CD15^negHLA-DR^negCD117⁺CD34^neg	4	2.8	<10
CD15^negHLA-DR^negCD117⁺CD34^neg	4
CD45^neg	1	0.7
CD13⁺CD33⁺CD45^negCD117⁺	1
Overexpression (n=10)	n=10	7.0	<10
HLA-DR⁺⁺	4	2.8	<10
CD117⁺ CD34^neg HLA-DR⁺⁺	2
CD34⁺ MM⁺ HLA-DR⁺⁺	1
CD117⁺ CD36^neg HLA-DR⁺⁺	1
CD13⁺⁺	4	2.8	<10
CD34⁺ CD133⁺ CD13⁺⁺	2
CD34⁺ CD117⁺CD13⁺⁺	2
CD33⁺⁺	1	0.7	<10
CD34⁺ CD117⁺ CD33⁺⁺	1
CD34⁺⁺	1	0.7	<10
CD117^neg CD19^negCD34⁺⁺	1

LAPs without immature markers (n=18)	n=18	12.6
CD13^neg	8	5.6	<10
CD15⁺CD14^negCD13^neg	5
CD15⁺CD34^negCD13^neg	1
CD15⁺CD33⁺CD13^neg	1
CD11b⁺HLA-DR⁺CD13^neg	1
CD56	3	2.1	<10
CD15⁺CD33⁺CD56⁺	1
CD14^negCD33⁺CD56⁺	1
HLA-DR⁺CD33⁺CD56⁺	1
CD14^neg	2	1.4	<10
CD15⁺CD13⁺CD14^neg	1
CD11b⁺HLA-DR^negCD14^neg	1
HLA-DR^neg	2	1.4	<10
CD15^negCD13⁺HLA-DR^neg	1
CD11b⁺CD36-DR^neg	1
HLA-DR⁺	1	0.7	<10
CD15⁺CD33⁺HLA-DR⁺	1
CD22	1	0.7	<10
CD33⁺HLA-DR⁺CD22⁺	1
CD33^dim	1	0.7	<10
CD34^negCD13⁺CD33^dim	1
Totald	143	100

Abbreviations: LAP, leukemia-associated (immuno)phenotype; MM, myeloid marker (usually CD13 or CD33, depending on diagnostic phenotype).

LAPs identified in the 64 BM samples using the standard immunophenotyping panel.

The mean number of LAPs per patients is 2.2 (143 LAPs/64 patients). In only one sample, no LAP could be defined.

A primitive marker (CD34, CD117 or CD133) was included in 125 of 143 (87%) of the LAPs.

‘Best consensus LAP' is defined as the LAP with highest sensitivity and specificity (see Results). More than one LAP may fulfill the same requirement, thereby defining more than one best consensus LAP per patient. As a result in the column used as ‘best consensus LAP (% of patients)', the total percentages exceed 100%.

CD34 alone was used in 42%, CD117 alone in 27% and CD133 alone in 5%, although any of the four possible combinations of at least two primitive markers were used in 18% of the cases (data not shown). In the latter cases, it was often possible to define for the same patient at least two LAPs based on different primitive markers.

LAPs with underexpression (usually absence) of markers were almost exclusively present in the group with asynchronous expression (data not shown) and not separately scored.

As two or more consensus LAPs were identified in many patients, the total number of consensus LAPs (i.e., 143) exceeded the total number of patients (i.e., 64).